A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1567-1573

  Roy, A C ^a   Park, S R ^b   Cunningham, D ^a   Kang, Y K ^c   Chao, Y ^d   Chen, L T ^e   Rees, C ^f   Lim, H Y ^g   Tabernero, J ^h   Ramos, F J ^h   Kujundzic, M ⁱ   Cardic, M B ^j   Yeh, C G ^k   de Gramont, A ^l  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b National Cancer Center   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ University of Zagreb School of Medicine   (Croatia)

^j UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^k PharmaEngine Inc 16F   (Taiwan)

^l HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

Docetaxel; Irinotecan; Liposomal irinotecan; Oesophago gastric cancer; Phase II; Second line

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; IRINOTECAN; PEP 02; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84878447869     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt002     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; CD004064.
3. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 2009; 10: 903-912.
4. Lordick F. Gastrointestinal cancer: salvage chemotherapy in gastric cancer-more than a straw? Nat Rev Clin Oncol 2012; 9: 312-313.
5. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
6. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
7. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
8. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
9. Kang JH, Lee SI, Lim do H et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518.
10. Ueda S, Hironaka S, Yasui H et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. ASCO Meeting Abstr 2012; 30: 4002.
11. Drummond DC, Noble CO, Guo Z et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006; 66: 3271-3277.
12. Chen L, Chang T, Cheng A, Yang C, Shiah H, Chang J, Yeh G. Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients. J Clin Oncol 2008; 29: 26.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Chen LT, Shiah HS, Lin PC, Lee JC, Su WC, Wang YW, Yeh GC, Chang JY. Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer after first-line oxaliplatin-based chemotherapy. J Clin Oncol 2012; 30(4): (abstr 613).
15. Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-151.
16. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33: 245-259.
17. Ko AH, Tempero MA, Shan Y et al. A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabinerefractory metastatic pancreatic cancer. ASCO Meeting Abstr 2011; 29: 4069.
18. Egner J, Goldberg RM, Sargent DJ et al. Group trial CPT-11 at 320 mg/m2 caused excessive toxicity in patients ( pts) with advanced adenocarcinoma(ACA) of the stomach (S) or gastroesophageal junction (GJ): A North Central Cancer Treatment. Proc Am Soc Clin Oncol 1999; 16: 207a.
19. Bang YJ, Kang WK, Kang YK et al. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002; 32: 248-254.
20. de Jong FA, Kehrer DF, Mathijssen RH et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006; 11: 944-954.
21. Cote JF, Kirzin S, Kramar A et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13: 3269-3275.
22. Toffoli G, Cecchin E, Corona G et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061-3068.
23. Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with nonsmall- cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-2244.
24. Jada SR, Lim R, Wong CI et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C
25. Minami H, Sai K, Saeki M et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007; 17: 497-504.
26. Palomaki GE, Bradley LA, Douglas MP et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11: 21-34.
27. Study of MM-398 with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer (NAPOLI 1). ClinicalTrials.gov Identifier: NCT01494506.